Novel prognostic scoring system for autologous hematopoietic cell transplantation in multiple myeloma

Binod Dhakal; Anita D’Souza; Natalie Callander; Saurabh Chhabra; Raphael Fraser; Omar Davila; Kenneth Anderson; Amer Assal; Sherif M. Badawy; Jesus Berdeja; Jan Cerny; Raymond Comenzo; Rajshekhar Chakraborty; Robert Peter Gale; Rammurti Kamble; Mohamed A. Kharfan-Dabaja; Maxwell Krem; Siddhartha Ganguly; Murali Janakiram; Ankit Kansagra; Reinhold Munker; Hemant Murthy; Sagar Patel; Shaji Kumar; Nina Shah; Muzaffar Qazilbash; Parameswaran Hari

doi:10.1111/bjh.16987

Novel prognostic scoring system for autologous hematopoietic cell transplantation in multiple myeloma

Binod Dhakal
, Anita D’Souza
, Natalie Callander
, Saurabh Chhabra
, Raphael Fraser
, Omar Davila
, Kenneth Anderson
, Amer Assal
, Sherif M. Badawy
, Jesus Berdeja
, Jan Cerny
, Raymond Comenzo
, Rajshekhar Chakraborty
, Robert Peter Gale
, Rammurti Kamble
, Mohamed A. Kharfan-Dabaja
, Maxwell Krem
, Siddhartha Ganguly
, Murali Janakiram
, Ankit Kansagra

Reinhold Munker, Hemant Murthy, Sagar Patel, Shaji Kumar, Nina Shah, Muzaffar Qazilbash, Parameswaran Hari

Producción científica: Article › revisión exhaustiva

12 Citas (Scopus)

Resumen

We studied 2,528 patients with upfront autologous haematopoietic cell transplantation (AHCT) for multiple myeloma (MM) from 2008–2017 to develop a prognostic model to predict outcomes. High-risk cytogenetics included t(4;14), t(14;16), t(14;20), del13q on karyotype, del17p, +1q or 1pdel. A Cox model identified factors prognostic of progression/relapse in a training subset (n = 1,246). A weighted score using these factors was assigned to a validation cohort (n = 774). Presence of high-risk cytogenetics [hazard ratio, (HR) 1·68 (1·3–2·17)] and pre-AHCT bone marrow plasma cells (BMPCs) ≥10% [1·68 (1·33–2·12)] were assigned 4 points each; albumin at diagnosis <3·5 g/dl [1·31 (1·07–1·61)] 2; standard risk cytogenetics 1, and no cytogenetics abnormality, BMPCs <10% at AHCT and albumin ≥3·5 g/dl at diagnosis 0 points each. A three-category system with low risk (0–3), intermediate risk (4–8) and high risk (9–10) showed 3-year progression-free survival in the low vs. intermediate vs. high risk of 58% (95% CI: 52–63) vs. 49% (95% CI: 43–56) vs. 31% (95% CI: 12–51), P < 0.001 respectively, and 3-year OS in low vs. intermediate vs. high risk of 88% (95% CI: 84–91) vs. 81% (95% CI: 76–86) vs. 64% (95% CI: 39–80); P < 0·001. Our prognostic scoring system can identify MM patients at risk for early relapse after AHCT.

Idioma original	English
Páginas (desde-hasta)	442-452
Número de páginas	11
Publicación	British Journal of Haematology
Volumen	191
N.º	3
DOI	https://doi.org/10.1111/bjh.16987
Estado	Published - nov 1 2020

Nota bibliográfica

Publisher Copyright:
© 2020 British Society for Haematology and John Wiley & Sons Ltd

Financiación

The CIBMTR is supported primarily by Public Health Service U24CA076518 from the National Cancer Institute (NCI), the National Heart, Lung and Blood Institute (NHLBI) and the National Institute of Allergy and Infectious Diseases (NIAID); U24HL138660 from NHLBI and NCI; OT3HL147741, R21HL140314 and U01HL128568 from the NHLBI; HHSH250201700006C, SC1MC31881‐01‐00 and HHSH250201700007C from the Health Resources and Services Administration (HRSA); and N00014‐18‐1‐2850, N00014‐18‐1‐2888, and N00014‐20‐1‐2705 from the Office of Naval Research; Additional federal support is provided by P01CA111412, R01CA152108, R01CA215134, R01CA218285, R01CA231141, R01HL126589, R01AI128775, R01HL129472, R01HL130388, R01HL131731, U01AI069197, U01AI126612, and BARDA. Support is also provided by Be the Match Foundation, Boston Children’s Hospital, Dana Farber, Japan Hematopoietic Cell Transplantation Data Center, St. Baldrick’s Foundation, the National Marrow Donor Program, the Medical College of Wisconsin and from the following commercial entities: AbbVie; Actinium Pharmaceuticals, Inc.; Adaptive Biotechnologies; Adienne SA; Allovir, Inc.; Amgen, Inc.; Anthem, Inc.; Astellas Pharma US; AstraZeneca; Atara Biotherapeutics, Inc.; bluebird bio, Inc.; Bristol Myers Squibb Co.; Celgene Corp.; Chimerix, Inc.; CSL Behring; CytoSen Therapeutics, Inc.; Daiichi Sankyo Co., Ltd.; Gamida‐Cell, Ltd.; Genzyme; GlaxoSmithKline (GSK); HistoGenetics, Inc.; Incyte Corporation; Janssen Biotech, Inc.; Janssen Pharmaceuticals, Inc.; Janssen/Johnson & Johnson; Jazz Pharmaceuticals, Inc.; Kiadis Pharma; Kite Pharma; Kyowa Kirin; Legend Biotech; Magenta Therapeutics; Mallinckrodt LLC; Medac GmbH; Merck & Company, Inc.; Merck Sharp & Dohme Corp.; Mesoblast; Millennium, the Takeda Oncology Co.; Miltenyi Biotec, Inc.; Novartis Oncology; Novartis Pharmaceuticals Corporation; Omeros Corporation; Oncoimmune, Inc.; Orca Biosystems, Inc.; Pfizer, Inc.; Pharmacyclics, LLC; Regeneron Pharmaceuticals, Inc.; REGiMMUNE Corp.; Sanofi Genzyme; Seattle Genetics; Sobi, Inc.; Takeda Oncology; Takeda Pharma; Terumo BCT; Viracor Eurofins and Xenikos BV. The views expressed in this article do not reflect the official policy or position of the National Institutes of Health, the Department of the Navy, the Department of Defense, Health Resources and Services Administration (HRSA) or any other agency of the U.S. Government. CIBMTR supports accessibility of research in accord with the National Institutes of Health (NIH) Data Sharing Policy and the National Cancer Institute Cancer Moonshot Public Access and Data Sharing Policy. The CIBMTR releases only de‐identified data sets that comply with all relevant global regulations regarding privacy and confidentiality. B.D. has served on the advisory board of Takeda, Amgen and Jansen and has received honorarium from Celgene; A.D’S. has received research funding from Takeda, Sanofi, TeneoBio and Mundipharma EDO and has consulted for Pfizer, Akcea, and Imbrium Therapeutics; M.AK‐D. reports other from Daiichi Sankyo and Pharmacyclics, outside the submitted work; N.S. received research funding, from Celgene, Janssen, Bluebird Bio Sutro Biopharma and Teneobio, N.S. has also acted in an advisory role for Genentech, Seattle Genetics, Oncopeptides, Karyopharm, Surface Oncology, Precision Biosciences GSK, Nektar, Amgen, Indapta Therapeutics, Sanofi, BMS, CareDx. Stock ownership and Indapta Therapeutics; A.A. reports grants from Incyte Corporation and personal fees from Incyte Corporation and Tolero Pharmaceuticals and grants from Regimmune, outside the submitted work; K.A. reports personal fees from Celgene, Janssen, Sanofi Aventis, Gilead, Millennium‐Takeda and Bristol Myers Squibb, outside of the submitted work; S.G. reports personal fees from Seattle Genetics, Kite Pharma and Kadmon, outside the submitted work; A.K. reports other from Takeda, Jansen, Pfizer, Karyopharm, Celgene/BMS and Sanofi, outside the submitted work; J.B. reports grants from Abbvie, Amgen, Acetylon, BioClinica, Bluebird, BMS, Celgene, Cellularity, Constellation, CRISPR, CURIS, EMD Sorono, Genentech, Glenmark, Janssen, Karyopharm, Kesios, Kite Pharma, Legend, Lilly, Novartis, Poseida, Prothena, Sanofi, Secura Bio, Sevier, Takeda, Teva, and Vivolux, outside the submitted work; S.K. reports grants and other from Abbvie, Celgene, Janssen, Takeda, Adaptive, KITE, Medimmune/Astra Zeneca, Oncopeptides and grants from Merck, Novartis, Roche and Sanofi, outside the submitted work; M.Q. reports other from Jenssen, Bioline, Angiocrine and Bioclinica, outside the submitted work; J.C. reports personal fees from Incyte Inc, Jazz Pharmaceuticals Inc., Daiichi‐Sankyo Inc., Pfizer Inc., outside the submitted work and owns stocks in Bluebird Bio Inc.

Financiadores	Número del financiador
Janssen/Johnson & Johnson
AMGen
Merck
Children's Hospital Boston
Dana-Farber Cancer Institute
CareDx Incorporated
CSL Behring
Takeda Pharmaceuticals U.S.A.
Teva Pharmaceutical Industries Ltd.
Intel Corporation
Biomedical Advanced Research and Development Authority
Janssen Biotech
AbbVie
Medical College of Wisconsin
Gilead Sciences
Daiichi Sankyo
HistoGenetics, Inc.
Chimerix Incorporated
Novartis
Daiichi‐Sankyo Inc.
Janssen Pharmaceuticals
Mundipharma EDO
Magenta Therapeutics
Sanofi
Pfizer
TeneoBio
Mallinckrodt LLC
Celgene
Match Foundation
CytoSen Therapeutics, Inc.
Office of Naval Research Naval Academy	P01CA111412, R01AI128775, R01CA231141, R01CA218285, U01AI069197, U01AI126612, R01HL129472, R01HL131731, R01HL130388, R01CA215134, R01HL126589, R01CA152108
U.S. Public Health Service	U24CA076518
Health Resources and Services Administration	N00014‐20‐1‐2705, N00014‐18‐1‐2850, N00014‐18‐1‐2888
National Institute of Allergy and Infectious F32-AI286447 Cydney N. Johnson Diseases National Institute of Allergy and Infectious R01AI168214 Jason W. Rosch Diseases National Institute of Allergy and Infectious P30 Cydney N. Johnson Diseases National Institute of Allergy and Infectious R00-AI166116 Christopher D. Radka Diseases National Institute of Allergy and Infectious T32-AI106700 Cydney N. Johnson Diseases National Institute of Allergy and Infectious R01AI192221 Jason W. Rosch Diseases National Inst...	OT3HL147741, R01AI128775, U01AI069197, U01AI126612, HHSH250201700007C, SC1MC31881‐01‐00
National Childhood Cancer Registry – National Cancer Institute	P01CA111412, R01CA231141, R01CA218285, U24CA076518, R01CA215134, R01CA152108
National Heart, Lung, and Blood Institute (NHLBI)	K23HL150232, U24HL138660, R01HL129472, R01HL130388, R01HL131731, R01HL126589, U01HL128568, R21HL140314

ASJC Scopus subject areas

Hematology

Acceder al documento

10.1111/bjh.16987

Otros archivos y enlaces

Citar esto

Dhakal, B., D’Souza, A., Callander, N., Chhabra, S., Fraser, R., Davila, O., Anderson, K., Assal, A., Badawy, S. M., Berdeja, J., Cerny, J., Comenzo, R., Chakraborty, R., Peter Gale, R., Kamble, R., Kharfan-Dabaja, M. A., Krem, M., Ganguly, S., Janakiram, M., ... Hari, P. (2020). Novel prognostic scoring system for autologous hematopoietic cell transplantation in multiple myeloma. British Journal of Haematology, 191(3), 442-452. https://doi.org/10.1111/bjh.16987

@article{ed44aed8bea14121ad9c7c815dbeb882,

title = "Novel prognostic scoring system for autologous hematopoietic cell transplantation in multiple myeloma",

abstract = "We studied 2,528 patients with upfront autologous haematopoietic cell transplantation (AHCT) for multiple myeloma (MM) from 2008{\textendash}2017 to develop a prognostic model to predict outcomes. High-risk cytogenetics included t(4;14), t(14;16), t(14;20), del13q on karyotype, del17p, +1q or 1pdel. A Cox model identified factors prognostic of progression/relapse in a training subset (n = 1,246). A weighted score using these factors was assigned to a validation cohort (n = 774). Presence of high-risk cytogenetics [hazard ratio, (HR) 1·68 (1·3{\textendash}2·17)] and pre-AHCT bone marrow plasma cells (BMPCs) ≥10\% [1·68 (1·33{\textendash}2·12)] were assigned 4 points each; albumin at diagnosis <3·5 g/dl [1·31 (1·07{\textendash}1·61)] 2; standard risk cytogenetics 1, and no cytogenetics abnormality, BMPCs <10\% at AHCT and albumin ≥3·5 g/dl at diagnosis 0 points each. A three-category system with low risk (0{\textendash}3), intermediate risk (4{\textendash}8) and high risk (9{\textendash}10) showed 3-year progression-free survival in the low vs. intermediate vs. high risk of 58\% (95\% CI: 52{\textendash}63) vs. 49\% (95\% CI: 43{\textendash}56) vs. 31\% (95\% CI: 12{\textendash}51), P < 0.001 respectively, and 3-year OS in low vs. intermediate vs. high risk of 88\% (95\% CI: 84{\textendash}91) vs. 81\% (95\% CI: 76{\textendash}86) vs. 64\% (95\% CI: 39{\textendash}80); P < 0·001. Our prognostic scoring system can identify MM patients at risk for early relapse after AHCT.",

keywords = "AHCT, MM, prognostic scoring system",

author = "Binod Dhakal and Anita D{\textquoteright}Souza and Natalie Callander and Saurabh Chhabra and Raphael Fraser and Omar Davila and Kenneth Anderson and Amer Assal and Badawy, \{Sherif M.\} and Jesus Berdeja and Jan Cerny and Raymond Comenzo and Rajshekhar Chakraborty and \{Peter Gale\}, Robert and Rammurti Kamble and Kharfan-Dabaja, \{Mohamed A.\} and Maxwell Krem and Siddhartha Ganguly and Murali Janakiram and Ankit Kansagra and Reinhold Munker and Hemant Murthy and Sagar Patel and Shaji Kumar and Nina Shah and Muzaffar Qazilbash and Parameswaran Hari",

note = "Publisher Copyright: {\textcopyright} 2020 British Society for Haematology and John Wiley \& Sons Ltd",

year = "2020",

month = nov,

day = "1",

doi = "10.1111/bjh.16987",

language = "English",

volume = "191",

pages = "442--452",

number = "3",

}

Dhakal, B, D’Souza, A, Callander, N, Chhabra, S, Fraser, R, Davila, O, Anderson, K, Assal, A, Badawy, SM, Berdeja, J, Cerny, J, Comenzo, R, Chakraborty, R, Peter Gale, R, Kamble, R, Kharfan-Dabaja, MA, Krem, M, Ganguly, S, Janakiram, M, Kansagra, A, Munker, R, Murthy, H, Patel, S, Kumar, S, Shah, N, Qazilbash, M & Hari, P 2020, 'Novel prognostic scoring system for autologous hematopoietic cell transplantation in multiple myeloma', British Journal of Haematology, vol. 191, n.º 3, pp. 442-452. https://doi.org/10.1111/bjh.16987

TY - JOUR

T1 - Novel prognostic scoring system for autologous hematopoietic cell transplantation in multiple myeloma

AU - Dhakal, Binod

AU - D’Souza, Anita

AU - Callander, Natalie

AU - Chhabra, Saurabh

AU - Fraser, Raphael

AU - Davila, Omar

AU - Anderson, Kenneth

AU - Assal, Amer

AU - Badawy, Sherif M.

AU - Berdeja, Jesus

AU - Cerny, Jan

AU - Comenzo, Raymond

AU - Chakraborty, Rajshekhar

AU - Peter Gale, Robert

AU - Kamble, Rammurti

AU - Kharfan-Dabaja, Mohamed A.

AU - Krem, Maxwell

AU - Ganguly, Siddhartha

AU - Janakiram, Murali

AU - Kansagra, Ankit

AU - Munker, Reinhold

AU - Murthy, Hemant

AU - Patel, Sagar

AU - Kumar, Shaji

AU - Shah, Nina

AU - Qazilbash, Muzaffar

AU - Hari, Parameswaran

PY - 2020/11/1

Y1 - 2020/11/1

N2 - We studied 2,528 patients with upfront autologous haematopoietic cell transplantation (AHCT) for multiple myeloma (MM) from 2008–2017 to develop a prognostic model to predict outcomes. High-risk cytogenetics included t(4;14), t(14;16), t(14;20), del13q on karyotype, del17p, +1q or 1pdel. A Cox model identified factors prognostic of progression/relapse in a training subset (n = 1,246). A weighted score using these factors was assigned to a validation cohort (n = 774). Presence of high-risk cytogenetics [hazard ratio, (HR) 1·68 (1·3–2·17)] and pre-AHCT bone marrow plasma cells (BMPCs) ≥10% [1·68 (1·33–2·12)] were assigned 4 points each; albumin at diagnosis <3·5 g/dl [1·31 (1·07–1·61)] 2; standard risk cytogenetics 1, and no cytogenetics abnormality, BMPCs <10% at AHCT and albumin ≥3·5 g/dl at diagnosis 0 points each. A three-category system with low risk (0–3), intermediate risk (4–8) and high risk (9–10) showed 3-year progression-free survival in the low vs. intermediate vs. high risk of 58% (95% CI: 52–63) vs. 49% (95% CI: 43–56) vs. 31% (95% CI: 12–51), P < 0.001 respectively, and 3-year OS in low vs. intermediate vs. high risk of 88% (95% CI: 84–91) vs. 81% (95% CI: 76–86) vs. 64% (95% CI: 39–80); P < 0·001. Our prognostic scoring system can identify MM patients at risk for early relapse after AHCT.

AB - We studied 2,528 patients with upfront autologous haematopoietic cell transplantation (AHCT) for multiple myeloma (MM) from 2008–2017 to develop a prognostic model to predict outcomes. High-risk cytogenetics included t(4;14), t(14;16), t(14;20), del13q on karyotype, del17p, +1q or 1pdel. A Cox model identified factors prognostic of progression/relapse in a training subset (n = 1,246). A weighted score using these factors was assigned to a validation cohort (n = 774). Presence of high-risk cytogenetics [hazard ratio, (HR) 1·68 (1·3–2·17)] and pre-AHCT bone marrow plasma cells (BMPCs) ≥10% [1·68 (1·33–2·12)] were assigned 4 points each; albumin at diagnosis <3·5 g/dl [1·31 (1·07–1·61)] 2; standard risk cytogenetics 1, and no cytogenetics abnormality, BMPCs <10% at AHCT and albumin ≥3·5 g/dl at diagnosis 0 points each. A three-category system with low risk (0–3), intermediate risk (4–8) and high risk (9–10) showed 3-year progression-free survival in the low vs. intermediate vs. high risk of 58% (95% CI: 52–63) vs. 49% (95% CI: 43–56) vs. 31% (95% CI: 12–51), P < 0.001 respectively, and 3-year OS in low vs. intermediate vs. high risk of 88% (95% CI: 84–91) vs. 81% (95% CI: 76–86) vs. 64% (95% CI: 39–80); P < 0·001. Our prognostic scoring system can identify MM patients at risk for early relapse after AHCT.

KW - AHCT

KW - MM

KW - prognostic scoring system

UR - https://www.scopus.com/pages/publications/85088463591

UR - https://www.scopus.com/pages/publications/85088463591#tab=citedBy

U2 - 10.1111/bjh.16987

DO - 10.1111/bjh.16987

M3 - Article

C2 - 33094839

AN - SCOPUS:85088463591

SN - 0007-1048

VL - 191

SP - 442

EP - 452

JO - British Journal of Haematology

JF - British Journal of Haematology

IS - 3

ER -

Novel prognostic scoring system for autologous hematopoietic cell transplantation in multiple myeloma

Resumen

Nota bibliográfica

Financiación

ASJC Scopus subject areas

Acceder al documento

Otros archivos y enlaces

Huella

Citar esto